Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Angelico

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
Alimentary Pharmacology & Therapeutics|February 27, 2004
A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapyM Angelico, M Cepparulo, F Angelico, et al.
Hepatology International|March 20, 2015
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcomeA Andriulli, F Morisco, A M Ippolito, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 26, 2018
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitroR Salpini, M Surdo, M F Cortese, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2015
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levelsV C Di Maio, V Cento, D Di Paolo, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
Alimentary Pharmacology & Therapeutics|February 27, 2004
A randomized controlled trial of amantadine plus interferon-alpha2a vs. interferon-alpha2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha2a monotherapyM Angelico, M Cepparulo, F Angelico, et al.
Hepatology International|March 20, 2015
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcomeA Andriulli, F Morisco, A M Ippolito, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|November 26, 2018
The novel HBx mutation F30V correlates with hepatocellular carcinoma in vivo, reduces hepatitis B virus replicative efficiency and enhances anti-apoptotic activity of HBx N terminus in vitroR Salpini, M Surdo, M F Cortese, et al.
The Journal of Antimicrobial Chemotherapy|December 19, 2015
HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levelsV C Di Maio, V Cento, D Di Paolo, et al.
Pageof 13